Published in Neuropsychopharmacology on November 01, 2006
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Neuroanatomical and neurochemical substrates of timing. Neuropsychopharmacology (2010) 2.63
Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des (2009) 1.51
How antipsychotics work-from receptors to reality. NeuroRx (2006) 1.12
Reality of auditory verbal hallucinations. Brain (2009) 1.04
Increased intrinsic brain activity in the striatum reflects symptom dimensions in schizophrenia. Schizophr Bull (2012) 1.02
Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) (2007) 0.95
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull (2012) 0.94
Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr (2011) 0.93
Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull (2008) 0.91
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.88
Neuropathological changes in the substantia nigra in schizophrenia but not depression. Eur Arch Psychiatry Clin Neurosci (2013) 0.85
In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [(11)C](R)-PK11195 positron emission tomography study. Mol Psychiatry (2016) 0.81
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull (2015) 0.81
An investigation into aripiprazole's partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Psychopharmacology (Berl) (2016) 0.80
Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. Int J Clin Pract (2014) 0.79
Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther (2012) 0.79
Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine. Ther Adv Psychopharmacol (2011) 0.78
How have developments in molecular imaging techniques furthered schizophrenia research? Imaging Med (2009) 0.77
18F-fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophr Res (2010) 0.76
Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study. Sci Rep (2016) 0.75
Model-based parametric study of frontostriatal abnormalities in schizophrenia patients. BMC Psychiatry (2010) 0.75
Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. J Psychiatr Res (2016) 0.75
Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions. Neuropsychopharmacology (2017) 0.75
Grand challenges in global mental health. Nature (2011) 8.40
Schizophrenia. Lancet (2009) 8.14
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry (2012) 4.54
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 4.18
Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron (2003) 2.99
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry (2007) 2.53
The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry (2012) 2.34
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry (2006) 2.21
Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.18
Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry (2003) 2.11
Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry (2013) 2.06
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry (2004) 2.00
Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry (2005) 2.00
Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry (2002) 1.96
A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res (2006) 1.81
Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology (2011) 1.78
Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med (2010) 1.75
Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry (2007) 1.72
A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res (2010) 1.68
An automated method for the extraction of regional data from PET images. Psychiatry Res (2006) 1.67
Separate brain regions code for salience vs. valence during reward prediction in humans. Hum Brain Mapp (2007) 1.64
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
A comparison of two delivery modalities of a mobile phone-based assessment for serious mental illness: native smartphone application vs text-messaging only implementations. J Med Internet Res (2013) 1.58
The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry (2012) 1.58
The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology (2007) 1.56
Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry (2012) 1.56
Microvascular abnormality in schizophrenia as shown by retinal imaging. Am J Psychiatry (2013) 1.53
Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. Am J Psychiatry (2002) 1.51
Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry (2010) 1.50
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry (2003) 1.49
D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol (2009) 1.48
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
"Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci (2007) 1.47
In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse (2009) 1.47
Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem (2006) 1.42
Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry (2007) 1.40
Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp (2008) 1.40
Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry (2002) 1.39
Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol Psychiatry (2007) 1.39
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res (2012) 1.38
First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology (2007) 1.38
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry (2012) 1.31
Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry (2003) 1.30
Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry (2008) 1.30
Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry (2012) 1.29
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (2012) 1.29
Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci (2005) 1.29
Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry (2012) 1.28
Structural brain abnormalities in patients with schizophrenia and 22q11 deletion syndrome. Biol Psychiatry (2002) 1.27
Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry (2004) 1.27
Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab (2006) 1.26
Integrating mobile-phone based assessment for psychosis into people's everyday lives and clinical care: a qualitative study. BMC Psychiatry (2013) 1.25
Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry (2009) 1.25
Strategies to enhance patient recruitment and retention in research involving patients with a first episode of mental illness. Contemp Clin Trials (2008) 1.25
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res (2006) 1.24
High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry (2005) 1.24
Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol (2005) 1.23
Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA. J Cereb Blood Flow Metab (2012) 1.22
Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology (2006) 1.22
Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry (2006) 1.22
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology (2005) 1.21
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry (2004) 1.21
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr Res (2008) 1.20
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry (2004) 1.20
Increased stress-induced dopamine release in psychosis. Biol Psychiatry (2011) 1.20
Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry (2010) 1.20